
Opinion|Videos|December 14, 2023
Program Development and SOPs for Bispecific Engagers
Author(s)Justin LaPorte, PharmD, BCOP
Justin LaPorte, PharmD, BCOP, further explores his experience in developing and/or executing program development and SOPs for bispecific engagers.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5

















